{"nctId":"NCT00316706","briefTitle":"Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine","startDateStruct":{"date":"2005-10"},"conditions":["Cervical Intraepithelial Neoplasia","Papillomavirus Infection"],"count":1245,"armGroups":[{"label":"Cervarix Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)"]},{"label":"Havrix Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Havrix™"]}],"interventions":[{"name":"GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)","otherNames":[]},{"name":"Havrix™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A female who enrolled in the immunological subset of the 580299-013 study, received the three doses of vaccine/control according to the treatment allocation and completed the 580299-013 study.\n* Written informed assent obtained from the subject and written informed consent obtained from a parent or legally acceptable representative of the subject.\n\nExclusion Criteria:\n\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n* Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.\n* Chronic administration of immunosuppressants or other immune-modifying drugs occurring less than 3 months prior to blood sampling.\n* Administration of immunoglobulins and/or any blood products within the 3 months preceding blood sampling.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"10 Years","maximumAge":"14 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3901.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3226.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2688.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2395.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1570.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1263.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"995.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"885.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Titers of Anti-3-O-desacyl-4'-Monophosphoryl Lipid A (Anti-MPL) Antibodies During the Initial 2 Years Follow-up","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as EL.U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"347.2","spread":null},{"groupId":"OG001","value":"117.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"271.5","spread":null},{"groupId":"OG001","value":"74.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Titers of Anti-3-O-desacyl 4'-Monophosphoryl Lipid A (Anti-MPL) Antibodies During the Last 2 Years Follow-up","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as EL.U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"224.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Pregnancies, Serious Adverse Events (SAEs), New Onset Chronic Diseases (NOCDs), and Conditions Prompting Emergency Room (ER) Visits or Physician Visits That Are Not Related to Common Diseases During the First 2 Years Follow-up","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.\n\nNew onset of chronic diseases (NOCDs) assessed include e.g. autoimmune disorders, asthma, type I diabetes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Pregnancies, Serious Adverse Events (SAEs), New Onset Chronic Diseases (NOCDs), and Conditions Prompting Emergency Room During the Last 2 Years Follow-up","description":"Serious adverse events assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.\n\nNew onset of chronic diseases (NOCDs) assessed include e.g. autoimmune disorders, asthma, type I diabetes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":626},"commonTop":[]}}}